Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Maravai Lifesciences Holdings Q3 2026 Results: Net Loss of $13.8M, Loss Narrows

Maravai LifeSciences Holdings, Inc. reported its Q3 2026 financial results, noting significant revenue dependency on CleanCap® for vaccine programs and ongoing risks from organizational changes and workforce reductions. As of October 29, 2026, the company had 149,254,467 Class A and 110,684,080 Class B shares outstanding, while maintaining its status as an accelerated filer.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue45.941.6
Gross profit16.25.7
Profit before tax-24.1-45.1
Net income-13.8-25.6
EPS (diluted, $ a share)$-0.09$-0.18

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+10.1%
Gross margin35.3%
Operating margin-45.0%
Source

10-Q filed with the SEC, NASDAQ: MRVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Maravai Lifesciences Holdings, Inc.: key numbers

Share price
$7.28Close, Nov 17
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Maravai Lifesciences Holdings, Inc.

All →
4:03 PM ET 8-K
Financial Results

Maravai Lifesciences Holdings Financial Results

Maravai LifeSciences reported Q3 2026 total revenue of $45.9 million, a 10% increase year-over-year, driven by strong demand for mRNA products and GMP consumables. The company narrowed its net loss to $24.0 million and raised its full-year 2026 revenue and Adjusted EBITDA guidance based on positive momentum in its TriLink and Cygnus segments.

Term
Q3 2026

“Our third- quarter results build on the momentum we established in the first half of the year. TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”

Bernd Brust, CEO of Maravai LifeSciences

“Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance.”

Bernd Brust, CEO of Maravai LifeSciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.